Pre-Seed Round Open

Invest in the Future of
Swiss Preventve Health

CHF 2M Pre-Seed round. First-mover in mobile preventve diagnostics. Addressing a CHF 2.5 billion market with zero direct competitors.

Request Full Prospectus View Thesis
CHF 2M
Pre-Seed Round
CHF 2.5bn
Market Size
10 mo
Van Payback
50%
Cost Advantage
Market Thesis

The Opportunity

Switzerland spends CHF 2.5 billion annually on preventve health, yet remains the only DACH country without a mobile diagnostic fleet.

TAM
CHF 2.5bn
Swiss preventve health
SAM
CHF 850M
Workplace screening
SOM
CHF 42M
Year 5 target

No Direct Competitor

No existing mobile fleet operator delivers employer-site preventve screening in Switzerland. The market is uncontested.

50% Cost Advantage

German telemedicine physicians (MEBEKO-recognized) provide clinical oversight at half the cost of Swiss-based doctors, a structural margin advantage.

Regulatory Moat

Institutional ZSR number + QUALAB accreditation + cantonal BAB approval create a multi-layer regulatory barrier that takes 12-18 months to replicate.

Capital-Efficient Scaling

Each van pays back within 10 months. Fleet expansion is modular: add vans, add cities, add revenue. No facility buildout required.

Revenue Model

Four Revenue Streams

Diversified revenue base across direct employer contracts, mandatory insurance, complementary coverage, and clinical trial recruitment.

Employer B2B

Direct contracts with Swiss employers for on-site preventve screening programmes. Per-employee, per-visit pricing.

~60%
of revenue (Year 3)

LAMal Billing

Mandatory insurance reimbursement for qualifying screenings (CRC, cardiovascular). Institutional ZSR number required.

~20%
of revenue (Year 3)

VVG Insurance

Complementary insurance partnerships for expanded screening panels. Premium wellness positioning for insurer members.

~12%
of revenue (Year 3)

Trial Recruitment

Clinical trial patient identification and pre-screening for pharma partners. High-margin, data-leveraged revenue.

~8%
of revenue (Year 3)

Detailed Materials Available Under NDA

Our financial model, unit economics, funding structure, regulatory timeline, and exit analysis are available to qualified investors upon signing a non-disclosure agreement.

Financial Model

10-sheet Excel with P&L, cash flow, sensitivity, unit economics

NDA Required

Funding Structure

Round details, dilution table, cap table, milestone gates

NDA Required

Unit Economics

Per-patient waterfall, per-van economics, break-even analysis

NDA Required

Regulatory Pathway

MEBEKO timeline, cantonal licensing, institutional ZSR model

On Request

Exit Analysis

Potential acquirers, valuation scenarios, comparable transactions

NDA Required

Full Whitepaper

30-section clinical, regulatory, and operational business plan

On Request
Request Access & NDA

How It Works

1

Request Access

Fill in the form below with your details and investment interest.

2

Sign NDA

We send you a mutual NDA. Once signed, you receive the full investor package.

3

Review & Meet

Review the materials, schedule a call with the founding team.

Request Full Prospectus

Access the complete investor materials including financial model, pitch deck, and whitepaper.

Includes:

Financial Model (10-sheet Excel)
Pitch Deck (PDF)
Full Whitepaper
Stakeholder Validations
Request Prospectus